| Over a quarter ago |
|
Conference/Events
|
EHA 2021 Virtual Congress… EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link ShowHide Related Items >><< - 05/19/21
- Acceleron gives interim results of Pulsar trial of sotatercept in PAH patients
- 05/19/21
- Acceleron presents SPECTRA Phase 2 Trial data on sotatercept in PAH
- 05/12/21
- Acceleron to present on Reblozyl at EHA2021
- 04/28/21
- Acceleron issued 'notice of noncompliance' by FDA related to data submission
VRTX Vertex Pharmaceuticals - 06/11/21
- Vertex Pharmaceuticals, Crispr Therapeutics announce new CTX001 data
- 06/10/21
- Vertex falls after ending development of liver disease drug VX-864
- 06/10/21
- Vertex will not advance VX-864 into late-stage development
- 06/10/21
- Vertex says primary endpoint achieved in Phase 2 study of VX-864
- 06/11/21
- TG Therapeutics announces data from Phase 1 study of TG-1701
- 06/04/21
- TG Therapeutics announces data from Phase 1 study of TG-1701
- 05/25/21
- TG Therapeutics announce FDA accepted BLA for ublituximab, UKONIQ combination
- 05/10/21
- TG Therapeutics announces 2021 key objectives
- 06/14/21
- Athira Pharma appoints Rachel Lenington as Chief Technology Officer
- 06/07/21
- SpringsWorks, Seagen enter collaboration for nirogacestat w/ SEA-BCMA
- 06/03/21
- Seagen's Tukysa combination shows improved survival in breast cancer
- 05/19/21
- Seagen and Astellas Pharma update results from trials of Padcev
RIGL Rigel Pharmaceuticals - 04/13/21
- Rigel announces results from Phase 2 clinical trial of fostamatinib
- 04/07/21
- Rigel Pharmaceuticals closes R552 licensing agreement with Eli Lilly
- 03/11/21
- Rigel Pharma completes patient enrollment for Phase 2 trial of fostamatinib
- 02/18/21
- Eli Lilly, Rigel Pharmaceuticals enter exclusive license agreement for R552
- 06/16/21
- uniQure enrolls first two patients in second cohort phase I/II trial of AMT-130
- 05/27/21
- uniQure says DSMB recommends proceeding with Phase I/II trial of AMT-130
- 05/13/21
- uniQure presents clinical data from phase III HOPE-B gene therapy trial
- 05/06/21
- uniQure receives $450M in commercialization, license agreement with CSL Behring
ORTX Orchard Therapeutics - 05/13/21
- Orchard Therapeutics expects cash, cash equivalents to fund operations into 2023
- 05/11/21
- Orchard Therapeutics announces publication of data evaluating OTL-101
- 03/03/21
- Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact
- 03/02/21
- Orchard Therapeutics expects cash to fund requirements into 1H23
MGTA Magenta Therapeutics - 06/14/21
- Magenta Therapeutics appoints Thomas Beetham as chief legal officer
- 05/12/21
- Magenta Therapeutics announces results from Phase 2 trial of MGTA-145
- 05/12/21
- Magenta Therapeutics announces $86.4M common stock investment
- 04/19/21
- Magenta Therapeutics appoints David Nichols as CTO
- 06/07/21
- MEI Pharma, Kyowa Kirin announce first patient dosed in phase 2 TIDAL study
- 05/12/21
- MEI Pharma, Kyowa Kirin to present data from Phase 1b study of zandelisib combo
- 04/30/21
- MEI Pharma promotes Richard Ghalie to Chief Medical Officer
- 04/13/21
- MEI Pharma completes enrollment in Phase 2 Tidal study
- 06/11/21
- Mustang Bio reports updated interim Phase 1/2 data for MB-106
- 06/07/21
- Mustang Bio to host KOL webinar on MB-106 CD20-targeted CAR T
- 05/18/21
- Mustang Bio, City of Hope dose first patient in Phase 1 trial of MB-101
- 05/12/21
- Mustang Bio announces MB-106 CD20-targeted CAR T data to be presented at EHA
- 06/11/21
- Keros Therapeutics presents clinical data from ALK2, KER-050
- 05/25/21
- Keros Therapeutics issued of U.S. patent for novel therapeutic proteins
- 05/14/21
- Keros Therapeutics present results from preclinical study of KER-012
- 03/25/21
- Keros Therapeutics announces anticipated 2021 corporate milestones
JAZZ Jazz Pharmaceuticals - 06/08/21
- Rapid development of Cannabinoid based medicinal products 'reaching new levels'
- 04/23/21
- GW Pharmaceuticals shareholders approve acquisition by Jazz Pharmaceuticals
- 04/20/21
- Jazz Pharma announces results from Phase 3 study of XywavTM oral solution
- 04/12/21
- Jazz Pharmaceuticals: FDA grants Priority Review of sNDA for Xywav
- 06/11/21
- Incyte announces FDA extension of ruxolitinib NDA review period
- 06/08/21
- Incyte announces U.S. FDA has extended sNDA review
- 06/04/21
- Incyte, MorphoSys announce three-year results from Phase 2 L-MIND study
- 06/01/21
- Eli Lilly to present data that Olumiant improved conditions in RA
- 06/04/21
- Imara to present data on IMR-687 in SCD at EHA Annual Congress
- 05/11/21
- Imara expects cash to fund planned operations into mid-2022
- 03/17/21
- Imara announces opening of higher dose arms in Phase 2b trials of IMR-687
- 03/05/21
- Imara to initiate pediatric clinical program of IMR-687 in 1H21
GBT Global Blood Therapeutics - 06/14/21
- Global Blood Therapeutics receives PIM designation for voxelotor from UK
- 06/04/21
- Global Blood Therapeutics announces employment inducement grants
- 05/13/21
- Point72 Asset Mgmgt reports 5.2% passive stake in Global Blood Therapeutics
- 05/07/21
- Global Blood Therapeutics announces employment inducement grants
- 06/11/21
- Forma Therapeutics announces new data from etavopivat trial
- 03/30/21
- Forma Therapeutics announces 'positive' FT-4202 600mg ascending dose data
- 01/20/21
- Forma Therapeutics announces first patient dosed in FT-7051 trial
- 06/11/21
- Equillium announces results from EQUATE study of itolizumab for aGVHD
- 06/10/21
- Equillium presents data on CD6 on T Cells with Itolizumab
- 06/07/21
- Equillium to colalborate with Oxford University, Kennedy Institute
- 05/17/21
- Equillium announces three presentations on itolizumab at the AAI
- 06/14/21
- Forma Therapeutics appoints John Bishop as CTO
- 05/06/21
- Epizyme sees current cash runway to extend into 2023
- 04/26/21
- Chimerix appoints Vicki Vakiener to board of directors
- 03/02/21
- Epizyme expects cash to fund initiatives into 2023
- 06/11/21
- Celyad presents preliminary IMMUNICY-1 trial data
- 05/05/21
- Celyad receives transparency notice from Tolefi SA
- 04/19/21
- Celyad appoints Charles Morris as CMO
- 01/18/21
- Celyad reports 10.6 months median overall survival in Phase 1 alloSHRINK trial
- 06/11/21
- Curis reports 'positive' data from ongoing Phase 1/2 study of CA-4948
- 05/12/21
- Curis trading resumes
- 05/12/21
- Curis announces two abstracts for CA-4948 to be presented at EHA2021
- 05/12/21
- Curis trading halted, volatility trading pause
- 06/10/21
- Protara Therapeutics appoints Jane Huang to board of directors
- 06/09/21
- Shoreline Bioscience and BeiGene in pact to develop NK-based cell therapeutics
- 06/07/21
- BeiGene announces acceptance of sBLA for tislelizumab in China
- 06/01/21
- BeiGene says data from Phase 3 ALPINE trial to be presented at EHA
- 06/11/21
- Aptose Biosciences releases highlights from corporate update at EHA
- 03/16/21
- Aptose Biosciences appoints George Melko as VP, regulatory affairs
- 05/25/21
- Biovitrum and Apellis report results from phase 3 PRINCE study
- 05/25/21
- Apellis, Swedish Orphan Biovitrum report results from Phase 3 Prince study
- 05/14/21
- Apellis Pharmaceuticals trading resumes
- 05/14/21
- Apellis announces FDA approval of EMPAVELI
- 06/07/21
- Alexion announces FDA approval of Ultomiris for adolescents, children in PNH
- 06/04/21
- AstraZeneca names Aradhana Sarin as new CFO
- 05/25/21
- U.K.'s CMA reviewing AstraZeneca's proposed purchase of Alexion
- 05/17/21
- Paulson buys Perpetua, exits American Equity in Q1
AGIO Agios Pharmaceuticals - 04/29/21
- Agios Pharmaceuticals expects cash to fund requirements through catalysts
- 04/29/21
- Agios Pharmaceuticals announces anticipated 2021 key milestones
- 04/01/21
- Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers
- 04/01/21
- Agios Pharmaceuticals closes oncology business sale to Servier
- 02/22/21 JonesTrading
- Aptose Biosciences resumed with a Buy at JonesTrading
- 10/19/20 Cantor Fitzgerald
- Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
- 09/22/20 Alliance Global Partners
- Aptose Biosciences initiated with a Buy at Alliance Global Partners
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 05/17/21 BTIG
- Mustang Bio initiated with a Buy at BTIG
- 05/17/21 BTIG
- Mustang Bio initiated with a Buy at BTIG
- 05/12/21 Cantor Fitzgerald
- Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
- 12/23/20 B. Riley
- Mustang Bio transferred with a Buy at B. Riley Securities
- 06/16/21 Chardan
- uniQure on track for 'powerful' Huntington's catalyst, says Chardan
- 06/14/21 BTIG
- uniQure initiated with a Buy at BTIG
- 05/20/21 UBS
- uniQure initiated with a Neutral at UBS
- 05/19/21 H.C. Wainwright
- uniQure price target raised to $90 from $80 at H.C. Wainwright
RIGL Rigel Pharmaceuticals - 06/11/21 BMO Capital
- Rigel Pharmaceuticals coverage transferred at BMO Capital
- 05/12/21 Cantor Fitzgerald
- Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
- 04/13/21 Piper Sandler
- Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
- 02/18/21 H.C. Wainwright
- Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics - 06/14/21 BTIG
- Magenta Therapeutics initiated with a Buy at BTIG
- 05/18/21 B. Riley
- Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
- 05/17/21 B. Riley
- Magenta Therapeutics initiated with a Buy at B. Riley
- 05/13/21 Mizuho
- Magenta Therapeutics price target raised to $17 from $16 at Mizuho
- 04/26/21 Wells Fargo
- MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
- 10/12/20 Brookline
- MEI Pharma initiated with a Buy at Brookline
- 09/22/20 Alliance Global Partners
- MEI Pharma initiated with a Buy at Alliance Global Partners
- 07/06/20 Truist
- MEI Pharma price target lowered to $12 from $16 at SunTrust
- 05/13/21 B. Riley
- Curis price target raised to $22 from $19 at B. Riley
- 05/13/21 Cantor Fitzgerald
- Curis price target raised to $24 from $15 at Cantor Fitzgerald
- 05/12/21 Cantor Fitzgerald
- Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
- 06/11/21 H.C. Wainwright
- Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
- 05/19/21 Piper Sandler
- Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
- 04/26/21 Credit Suisse
- Acceleron assumed with an Outperform at Credit Suisse
- 03/23/21
- Fly Intel: Top five analyst downgrades
- 05/07/21 SVB Leerink
- Epizyme upgraded to Outperform from Market Perform at SVB Leerink
- 04/23/21 Cowen
- Epizyme transferred with Outperform at Cowen
- 03/30/21 Credit Suisse
- Epizyme initiated with an Outperform at Credit Suisse
- 03/30/21 Credit Suisse
- Epizyme initiated with an Outperform at Credit Suisse
- 02/10/21 SVB Leerink
- Incyte downgraded to Market Perform from Outperform at SVB Leerink
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/04/21 Guggenheim
- Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics - 03/10/21 Stifel
- Stifel says Bluebird update on AML provides 'some relief' to other LV players
- 03/02/21 JPMorgan
- Orchard Therapeutics assumed with an Overweight at JPMorgan
- 03/01/21 Stifel
- Orchard Therapeutics initiated with a Buy at Stifel
- 02/18/21 Goldman Sachs
- Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
- 04/20/21
- Fly Intel: Top five analyst initiations
- 04/20/21 Goldman Sachs
- TG Therapeutics initiated with a Neutral at Goldman Sachs
- 04/19/21 Cantor Fitzgerald
- TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
- 04/19/21 H.C. Wainwright
- TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
- 03/03/21
- Fly Intel: Top five analyst initiations
- 03/03/21 JonesTrading
- Equillium initiated with a Buy at JonesTrading
- 11/30/20 H.C. Wainwright
- Equillium price target lowered to $12 from $22 at H.C. Wainwright
- 07/14/20 H.C. Wainwright
- Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals - 05/19/21
- Fly Intel: Top five analyst initiations
- 05/19/21 JPMorgan
- Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
- 05/17/21 H.C. Wainwright
- Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
- 04/21/21 Cantor Fitzgerald
- Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals - 06/14/21 Truist
- Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
- 06/14/21 SVB Leerink
- Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
- 06/14/21 Deutsche Bank
- Grifols upgraded to Buy from Hold at Deutsche Bank
- 06/13/21 Piper Sandler
- Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
- 05/17/21 Evercore ISI
- Seagen initiated with an In Line at Evercore ISI
- 04/30/21 Piper Sandler
- Seagen price target lowered to $160 from $170 at Piper Sandler
- 04/12/21 B. Riley
- B. Riley calls Agenus the next Seagen, reiterates $8 target
- 03/30/21 Credit Suisse
- Seagen initiated with a Neutral at Credit Suisse
- 03/08/21 SVB Leerink
- Imara price target lowered to $42 from $59 at SVB Leerink
- 01/06/21 SVB Leerink
- Imara selloff a potential buying opportunity, says SVB Leerink
- 08/17/20
- Fly Intel: Top five analyst upgrades
- 08/17/20 Citi
- Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics - 05/07/21 Cantor Fitzgerald
- Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
- 05/06/21 Piper Sandler
- Global Blood price target lowered to $45 from $50 at Piper Sandler
- 04/14/21
- Fly Intel: Top five analyst initiations
- 04/14/21 SVB Leerink
- SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
- 06/14/21 SVB Leerink
- BeiGene price target raised to $417 from $388 at SVB Leerink
- 03/16/21 HSBC
- BeiGene price target raised to $385 from $296 at HSBC
- 03/08/21 China Renaissance
- BeiGene initiated with a Buy at China Renaissance
- 03/04/21 Goldman Sachs
- Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
- 05/20/21 UBS
- Apellis initiated with a Buy at UBS
- 05/18/21 BMO Capital
- Apellis price target raised to $68 from $64 at BMO Capital
- 05/17/21 Oppenheimer
- Apellis price target raised to $67 from $64 at Oppenheimer
- 05/17/21 Raymond James
- Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals - 06/10/21 H.C. Wainwright
- Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 04/30/21 Goldman Sachs
- Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
- 04/30/21 Barclays
- Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
- 03/30/21 Piper Sandler
- Agios should rally on Forma Therapeutics data, says Piper Sandler
- 03/31/21 H.C. Wainwright
- Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
- 02/17/21
- Fly Intel: Top five analyst initiations
- 02/17/21 Oppenheimer
- Forma Therapeutics initiated with an Outperform at Oppenheimer
- 12/08/20 SVB Leerink
- Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
- 12/08/20 H.C. Wainwright
- Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
- 12/08/20 Piper Sandler
- Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
- 11/18/20 Piper Sandler
- Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
- 03/25/21 JonesTrading
- Celyad downgraded to Hold from Buy at JonesTrading
- 12/08/20 H.C. Wainwright
- Celyad price target lowered to $18 from $22 at H.C. Wainwright
- 05/05/21
- Fly Intel: Top five analyst upgrades
- 05/05/21 Oppenheimer
- Alexion upgraded to Outperform from Perform at Oppenheimer
- 05/03/21 SVB Leerink
- Alexion price target raised to $173 from $156 at SVB Leerink
- 04/30/21 Wedbush
- Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
- 05/06/21
- Acceleron reports Q1 EPS (77c), consensus (81c)
- 02/25/21
- Acceleron reports Q4 EPS (95c), consensus (59c)
VRTX Vertex Pharmaceuticals - 04/29/21
- Vertex Pharmaceuticals backs FY21 revenue view $6.7B-$6.9B, consensus $6.95B
- 04/29/21
- Vertex Pharmaceuticals reports Q1 EPS $2.98, consensus $2.69
- 04/29/21
- Notable companies reporting after market close
- 02/01/21
- Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59
- 05/10/21
- TG Therapeutics reports Q1 EPS (69c), consensus (49c)
- 03/02/21
- TG Therapeutics reports Q4 EPS (71c), consensus (58c)
- 04/29/21
- Seagen reports Q1 EPS (67c), consensus (61c)
- 02/11/21
- Seagen reports Q4 EPS 90c, consensus 86c
RIGL Rigel Pharmaceuticals - 05/05/21
- Rigel Pharmaceuticals reports Q1 EPS 23c, consensus 0c
- 03/02/21
- Rigel Pharmaceuticals reports Q4 EPS (11c), consensus (11c)
- 01/11/21
- Rigel Pharmaceuticals sees Q4 revenue approximately $18.4M, consensus $17.81M
- 05/10/21
- uniQure reports Q1 EPS (91c), consensus (88c)
- 03/01/21
- uniQure reports 2020 EPS ($2.81), consensus ($1.25)
ORTX Orchard Therapeutics - 05/13/21
- Orchard Therapeutics reports Q1 EPS (31c), consensus (33c)
- 03/02/21
- Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year
MGTA Magenta Therapeutics - 05/06/21
- Magenta Therapeutics reports Q1 EPS (36c), consensus (40c)
- 03/03/21
- Magenta Therapeutics reports Q4 EPS (38c), consensus (41c)
- 05/06/21
- MEI Pharma reports Q3 EPS (28c), consensus (16c)
- 02/04/21
- MEI Pharma reports Q2 EPS (16c), consensus (13c)
- 05/14/21
- Mustang Bio reports Q1 EPS (19c), consensus (19c)
- 03/24/21
- Mustang Bio reports FY20 EPS ($1.14), consensus ($1.01)
- 03/25/21
- Keros Therapeutics reports Q4 EPS (49c), consensus (57c)
JAZZ Jazz Pharmaceuticals - 05/04/21
- Jazz Pharmaceuticals backs FY21 adjusted EPS view $15.65-$16.85
- 05/04/21
- Jazz Pharmaceuticals reports Q1 EPS $3.92, consensus $3.71
- 02/23/21
- Jazz Pharmaceuticals sees FY21 adjusted EPS $15.65-$16.85, consensus $16.78
- 02/23/21
- Jazz Pharmaceuticals reports Q4 EPS $4.00, consensus $4.20
- 05/04/21
- Incyte reports Q1 EPS 67c, consensus 64c
- 02/09/21
- Incyte reports Q4 EPS 93c, consensus 75c
- 02/08/21
- Notable companies reporting before tomorrow's open
- 05/11/21
- Imara reports Q1 EPS (58), two est. (83c)
- 03/05/21
- Imara reports 2020 EPS ($3.53), consensus ($3.82)
GBT Global Blood Therapeutics - 05/05/21
- Global Blood Therapeutics reports Q1 EPS ($1.21), consensus ($1.01)
- 02/24/21
- Global Blood Therapeutics reports Q4 EPS ($1.00) , consensus (94c)
- 05/14/21
- Forma Therapeutics reports Q1 EPS (76c), consensus (76c)
- 03/30/21
- Forma Therapeutics reports Q4 EPS (68c), consensus (80c)
- 05/13/21
- Equillium reports Q1 EPS (33c), consensus (32c)
- 05/13/21
- Equillium reports Q1 EPS (33c), consensus (32c)
- 03/24/21
- Equillium reports Q4 EPS (36c), consensus (38c)
- 05/06/21
- Epizyme reports Q1 EPS (69c), consensus (57c)
- 02/23/21
- Epizyme reports Q4 EPS (65c), consensus (58c)
- 05/12/21
- Curis reports Q1 EPS (11c), consensus (9c)
- 03/16/21
- Curis reports Q4 EPS (11c), consensus (9c)
- 05/06/21
- BeiGene reports Q1 EPS 69c vs. ($4.70) a year ago.
- 02/25/21
- BeiGene reports Q4 EPS ($5.20), consensus ($4.81)
- 03/23/21
- Aptose Biosciences reports Q4 EPS (17c), consensus (14c)
- 04/28/21
- Apellis reports Q1 EPS ($2.32), consensus ($1.62)
- 02/25/21
- Apellis reports Q EPS 93c, consensus (75c)
- 04/30/21
- Alexion reports Q1 EPS $3.52, consensus $3.16
- 02/04/21
- Alexion reports Q4 EPS $2.96, consensus $2.56
- 02/04/21
- Alexion reports Q4 EPS $2.96, consensus $2.56
AGIO Agios Pharmaceuticals - 04/29/21
- Agios Pharmaceuticals reports Q1 EPS ($1.31), consensus ($1.32)
- 02/25/21
- Agios Pharmaceuticals reports Q4 EPS ($1.41), consensus ($1.33)
|
|
Conference/Events
|
EHA 2021 Virtual Congress… EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link ShowHide Related Items >><< - 05/19/21
- Acceleron gives interim results of Pulsar trial of sotatercept in PAH patients
- 05/19/21
- Acceleron presents SPECTRA Phase 2 Trial data on sotatercept in PAH
- 05/12/21
- Acceleron to present on Reblozyl at EHA2021
- 04/28/21
- Acceleron issued 'notice of noncompliance' by FDA related to data submission
VRTX Vertex Pharmaceuticals - 06/11/21
- Vertex Pharmaceuticals, Crispr Therapeutics announce new CTX001 data
- 06/10/21
- Vertex falls after ending development of liver disease drug VX-864
- 06/10/21
- Vertex will not advance VX-864 into late-stage development
- 06/10/21
- Vertex says primary endpoint achieved in Phase 2 study of VX-864
- 06/11/21
- TG Therapeutics announces data from Phase 1 study of TG-1701
- 06/04/21
- TG Therapeutics announces data from Phase 1 study of TG-1701
- 05/25/21
- TG Therapeutics announce FDA accepted BLA for ublituximab, UKONIQ combination
- 05/10/21
- TG Therapeutics announces 2021 key objectives
- 06/14/21
- Athira Pharma appoints Rachel Lenington as Chief Technology Officer
- 06/07/21
- SpringsWorks, Seagen enter collaboration for nirogacestat w/ SEA-BCMA
- 06/03/21
- Seagen's Tukysa combination shows improved survival in breast cancer
- 05/19/21
- Seagen and Astellas Pharma update results from trials of Padcev
RIGL Rigel Pharmaceuticals - 04/13/21
- Rigel announces results from Phase 2 clinical trial of fostamatinib
- 04/07/21
- Rigel Pharmaceuticals closes R552 licensing agreement with Eli Lilly
- 03/11/21
- Rigel Pharma completes patient enrollment for Phase 2 trial of fostamatinib
- 02/18/21
- Eli Lilly, Rigel Pharmaceuticals enter exclusive license agreement for R552
- 05/27/21
- uniQure says DSMB recommends proceeding with Phase I/II trial of AMT-130
- 05/13/21
- uniQure presents clinical data from phase III HOPE-B gene therapy trial
- 05/06/21
- uniQure receives $450M in commercialization, license agreement with CSL Behring
- 04/26/21
- uniQure announces removal of clinical hold on hemophiilia B gene therapy program
ORTX Orchard Therapeutics - 05/13/21
- Orchard Therapeutics expects cash, cash equivalents to fund operations into 2023
- 05/11/21
- Orchard Therapeutics announces publication of data evaluating OTL-101
- 03/03/21
- Orchard Therapeutics, Be The Match BioTherapies, extend Libmeldy pact
- 03/02/21
- Orchard Therapeutics expects cash to fund requirements into 1H23
MGTA Magenta Therapeutics - 06/14/21
- Magenta Therapeutics appoints Thomas Beetham as chief legal officer
- 05/12/21
- Magenta Therapeutics announces results from Phase 2 trial of MGTA-145
- 05/12/21
- Magenta Therapeutics announces $86.4M common stock investment
- 04/19/21
- Magenta Therapeutics appoints David Nichols as CTO
- 06/07/21
- MEI Pharma, Kyowa Kirin announce first patient dosed in phase 2 TIDAL study
- 05/12/21
- MEI Pharma, Kyowa Kirin to present data from Phase 1b study of zandelisib combo
- 04/30/21
- MEI Pharma promotes Richard Ghalie to Chief Medical Officer
- 04/13/21
- MEI Pharma completes enrollment in Phase 2 Tidal study
- 06/11/21
- Mustang Bio reports updated interim Phase 1/2 data for MB-106
- 06/07/21
- Mustang Bio to host KOL webinar on MB-106 CD20-targeted CAR T
- 05/18/21
- Mustang Bio, City of Hope dose first patient in Phase 1 trial of MB-101
- 05/12/21
- Mustang Bio announces MB-106 CD20-targeted CAR T data to be presented at EHA
- 06/11/21
- Keros Therapeutics presents clinical data from ALK2, KER-050
- 05/25/21
- Keros Therapeutics issued of U.S. patent for novel therapeutic proteins
- 05/14/21
- Keros Therapeutics present results from preclinical study of KER-012
- 03/25/21
- Keros Therapeutics announces anticipated 2021 corporate milestones
JAZZ Jazz Pharmaceuticals - 06/08/21
- Rapid development of Cannabinoid based medicinal products 'reaching new levels'
- 04/23/21
- GW Pharmaceuticals shareholders approve acquisition by Jazz Pharmaceuticals
- 04/20/21
- Jazz Pharma announces results from Phase 3 study of XywavTM oral solution
- 04/12/21
- Jazz Pharmaceuticals: FDA grants Priority Review of sNDA for Xywav
- 06/11/21
- Incyte announces FDA extension of ruxolitinib NDA review period
- 06/08/21
- Incyte announces U.S. FDA has extended sNDA review
- 06/04/21
- Incyte, MorphoSys announce three-year results from Phase 2 L-MIND study
- 06/01/21
- Eli Lilly to present data that Olumiant improved conditions in RA
- 06/04/21
- Imara to present data on IMR-687 in SCD at EHA Annual Congress
- 05/11/21
- Imara expects cash to fund planned operations into mid-2022
- 03/17/21
- Imara announces opening of higher dose arms in Phase 2b trials of IMR-687
- 03/05/21
- Imara to initiate pediatric clinical program of IMR-687 in 1H21
GBT Global Blood Therapeutics - 06/14/21
- Global Blood Therapeutics receives PIM designation for voxelotor from UK
- 06/04/21
- Global Blood Therapeutics announces employment inducement grants
- 05/13/21
- Point72 Asset Mgmgt reports 5.2% passive stake in Global Blood Therapeutics
- 05/07/21
- Global Blood Therapeutics announces employment inducement grants
- 06/11/21
- Forma Therapeutics announces new data from etavopivat trial
- 03/30/21
- Forma Therapeutics announces 'positive' FT-4202 600mg ascending dose data
- 01/20/21
- Forma Therapeutics announces first patient dosed in FT-7051 trial
- 06/11/21
- Equillium announces results from EQUATE study of itolizumab for aGVHD
- 06/10/21
- Equillium presents data on CD6 on T Cells with Itolizumab
- 06/07/21
- Equillium to colalborate with Oxford University, Kennedy Institute
- 05/17/21
- Equillium announces three presentations on itolizumab at the AAI
- 06/14/21
- Forma Therapeutics appoints John Bishop as CTO
- 05/06/21
- Epizyme sees current cash runway to extend into 2023
- 04/26/21
- Chimerix appoints Vicki Vakiener to board of directors
- 03/02/21
- Epizyme expects cash to fund initiatives into 2023
- 06/11/21
- Celyad presents preliminary IMMUNICY-1 trial data
- 05/05/21
- Celyad receives transparency notice from Tolefi SA
- 04/19/21
- Celyad appoints Charles Morris as CMO
- 01/18/21
- Celyad reports 10.6 months median overall survival in Phase 1 alloSHRINK trial
- 06/11/21
- Curis reports 'positive' data from ongoing Phase 1/2 study of CA-4948
- 05/12/21
- Curis trading resumes
- 05/12/21
- Curis announces two abstracts for CA-4948 to be presented at EHA2021
- 05/12/21
- Curis trading halted, volatility trading pause
- 06/10/21
- Protara Therapeutics appoints Jane Huang to board of directors
- 06/09/21
- Shoreline Bioscience and BeiGene in pact to develop NK-based cell therapeutics
- 06/07/21
- BeiGene announces acceptance of sBLA for tislelizumab in China
- 06/01/21
- BeiGene says data from Phase 3 ALPINE trial to be presented at EHA
- 06/11/21
- Aptose Biosciences releases highlights from corporate update at EHA
- 03/16/21
- Aptose Biosciences appoints George Melko as VP, regulatory affairs
- 05/25/21
- Biovitrum and Apellis report results from phase 3 PRINCE study
- 05/25/21
- Apellis, Swedish Orphan Biovitrum report results from Phase 3 Prince study
- 05/14/21
- Apellis Pharmaceuticals trading resumes
- 05/14/21
- Apellis announces FDA approval of EMPAVELI
- 06/07/21
- Alexion announces FDA approval of Ultomiris for adolescents, children in PNH
- 06/04/21
- AstraZeneca names Aradhana Sarin as new CFO
- 05/25/21
- U.K.'s CMA reviewing AstraZeneca's proposed purchase of Alexion
- 05/17/21
- Paulson buys Perpetua, exits American Equity in Q1
AGIO Agios Pharmaceuticals - 04/29/21
- Agios Pharmaceuticals expects cash to fund requirements through catalysts
- 04/29/21
- Agios Pharmaceuticals announces anticipated 2021 key milestones
- 04/01/21
- Agios Pharmaceuticals enters agreement to repurchase stock from Bristol-Myers
- 04/01/21
- Agios Pharmaceuticals closes oncology business sale to Servier
- 02/22/21 JonesTrading
- Aptose Biosciences resumed with a Buy at JonesTrading
- 10/19/20 Cantor Fitzgerald
- Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
- 09/22/20 Alliance Global Partners
- Aptose Biosciences initiated with a Buy at Alliance Global Partners
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 05/17/21 BTIG
- Mustang Bio initiated with a Buy at BTIG
- 05/17/21 BTIG
- Mustang Bio initiated with a Buy at BTIG
- 05/12/21 Cantor Fitzgerald
- Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
- 12/23/20 B. Riley
- Mustang Bio transferred with a Buy at B. Riley Securities
- 06/14/21 BTIG
- uniQure initiated with a Buy at BTIG
- 05/20/21 UBS
- uniQure initiated with a Neutral at UBS
- 05/19/21 H.C. Wainwright
- uniQure price target raised to $90 from $80 at H.C. Wainwright
- 04/26/21 Chardan
- Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals - 06/11/21 BMO Capital
- Rigel Pharmaceuticals coverage transferred at BMO Capital
- 05/12/21 Cantor Fitzgerald
- Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
- 04/13/21 Piper Sandler
- Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
- 02/18/21 H.C. Wainwright
- Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics - 06/14/21 BTIG
- Magenta Therapeutics initiated with a Buy at BTIG
- 05/18/21 B. Riley
- Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
- 05/17/21 B. Riley
- Magenta Therapeutics initiated with a Buy at B. Riley
- 05/13/21 Mizuho
- Magenta Therapeutics price target raised to $17 from $16 at Mizuho
- 04/26/21 Wells Fargo
- MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
- 10/12/20 Brookline
- MEI Pharma initiated with a Buy at Brookline
- 09/22/20 Alliance Global Partners
- MEI Pharma initiated with a Buy at Alliance Global Partners
- 07/06/20 Truist
- MEI Pharma price target lowered to $12 from $16 at SunTrust
- 05/13/21 B. Riley
- Curis price target raised to $22 from $19 at B. Riley
- 05/13/21 Cantor Fitzgerald
- Curis price target raised to $24 from $15 at Cantor Fitzgerald
- 05/12/21 Cantor Fitzgerald
- Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
- 06/11/21 H.C. Wainwright
- Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
- 05/19/21 Piper Sandler
- Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
- 04/26/21 Credit Suisse
- Acceleron assumed with an Outperform at Credit Suisse
- 03/23/21
- Fly Intel: Top five analyst downgrades
- 05/07/21 SVB Leerink
- Epizyme upgraded to Outperform from Market Perform at SVB Leerink
- 04/23/21 Cowen
- Epizyme transferred with Outperform at Cowen
- 03/30/21 Credit Suisse
- Epizyme initiated with an Outperform at Credit Suisse
- 03/30/21 Credit Suisse
- Epizyme initiated with an Outperform at Credit Suisse
- 02/10/21 SVB Leerink
- Incyte downgraded to Market Perform from Outperform at SVB Leerink
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/07/21 Truist
- Incyte initiated with a Buy at Truist
- 01/04/21 Guggenheim
- Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics - 03/10/21 Stifel
- Stifel says Bluebird update on AML provides 'some relief' to other LV players
- 03/02/21 JPMorgan
- Orchard Therapeutics assumed with an Overweight at JPMorgan
- 03/01/21 Stifel
- Orchard Therapeutics initiated with a Buy at Stifel
- 02/18/21 Goldman Sachs
- Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
- 04/20/21
- Fly Intel: Top five analyst initiations
- 04/20/21 Goldman Sachs
- TG Therapeutics initiated with a Neutral at Goldman Sachs
- 04/19/21 Cantor Fitzgerald
- TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
- 04/19/21 H.C. Wainwright
- TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
- 03/03/21
- Fly Intel: Top five analyst initiations
- 03/03/21 JonesTrading
- Equillium initiated with a Buy at JonesTrading
- 11/30/20 H.C. Wainwright
- Equillium price target lowered to $12 from $22 at H.C. Wainwright
- 07/14/20 H.C. Wainwright
- Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals - 05/19/21
- Fly Intel: Top five analyst initiations
- 05/19/21 JPMorgan
- Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
- 05/17/21 H.C. Wainwright
- Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
- 04/21/21 Cantor Fitzgerald
- Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals - 06/14/21 Truist
- Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
- 06/14/21 SVB Leerink
- Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
- 06/14/21 Deutsche Bank
- Grifols upgraded to Buy from Hold at Deutsche Bank
- 06/13/21 Piper Sandler
- Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
- 05/17/21 Evercore ISI
- Seagen initiated with an In Line at Evercore ISI
- 04/30/21 Piper Sandler
- Seagen price target lowered to $160 from $170 at Piper Sandler
- 04/12/21 B. Riley
- B. Riley calls Agenus the next Seagen, reiterates $8 target
- 03/30/21 Credit Suisse
- Seagen initiated with a Neutral at Credit Suisse
- 03/08/21 SVB Leerink
- Imara price target lowered to $42 from $59 at SVB Leerink
- 01/06/21 SVB Leerink
- Imara selloff a potential buying opportunity, says SVB Leerink
- 08/17/20
- Fly Intel: Top five analyst upgrades
- 08/17/20 Citi
- Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics - 05/07/21 Cantor Fitzgerald
- Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
- 05/06/21 Piper Sandler
- Global Blood price target lowered to $45 from $50 at Piper Sandler
- 04/14/21
- Fly Intel: Top five analyst initiations
- 04/14/21 SVB Leerink
- SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
- 06/14/21 SVB Leerink
- BeiGene price target raised to $417 from $388 at SVB Leerink
- 03/16/21 HSBC
- BeiGene price target raised to $385 from $296 at HSBC
- 03/08/21 China Renaissance
- BeiGene initiated with a Buy at China Renaissance
- 03/04/21 Goldman Sachs
- Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
- 05/20/21 UBS
- Apellis initiated with a Buy at UBS
- 05/18/21 BMO Capital
- Apellis price target raised to $68 from $64 at BMO Capital
- 05/17/21 Oppenheimer
- Apellis price target raised to $67 from $64 at Oppenheimer
- 05/17/21 Raymond James
- Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals - 06/10/21 H.C. Wainwright
- Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 04/30/21 Goldman Sachs
- Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
- 04/30/21 Barclays
- Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
- 03/30/21 Piper Sandler
- Agios should rally on Forma Therapeutics data, says Piper Sandler
- 03/31/21 H.C. Wainwright
- Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
- 02/17/21
- Fly Intel: Top five analyst initiations
- 02/17/21 Oppenheimer
- Forma Therapeutics initiated with an Outperform at Oppenheimer
- 12/08/20 SVB Leerink
- Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
- 12/08/20 H.C. Wainwright
- Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
- 12/08/20 Piper Sandler
- Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
- 11/18/20 Piper Sandler
- Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
- 03/25/21 JonesTrading
- Celyad downgraded to Hold from Buy at JonesTrading
- 12/08/20 H.C. Wainwright
- Celyad price target lowered to $18 from $22 at H.C. Wainwright
- 05/05/21
- Fly Intel: Top five analyst upgrades
- 05/05/21 Oppenheimer
- Alexion upgraded to Outperform from Perform at Oppenheimer
- 05/03/21 SVB Leerink
- Alexion price target raised to $173 from $156 at SVB Leerink
- 04/30/21 Wedbush
- Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
- 05/06/21
- Acceleron reports Q1 EPS (77c), consensus (81c)
- 02/25/21
- Acceleron reports Q4 EPS (95c), consensus (59c)
VRTX Vertex Pharmaceuticals - 04/29/21
- Vertex Pharmaceuticals backs FY21 revenue view $6.7B-$6.9B, consensus $6.95B
- 04/29/21
- Vertex Pharmaceuticals reports Q1 EPS $2.98, consensus $2.69
- 04/29/21
- Notable companies reporting after market close
- 02/01/21
- Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59
- 05/10/21
- TG Therapeutics reports Q1 EPS (69c), consensus (49c)
- 03/02/21
- TG Therapeutics reports Q4 EPS (71c), consensus (58c)
- 04/29/21
- Seagen reports Q1 EPS (67c), consensus (61c)
- 02/11/21
- Seagen reports Q4 EPS 90c, consensus 86c
RIGL Rigel Pharmaceuticals - 05/05/21
- Rigel Pharmaceuticals reports Q1 EPS 23c, consensus 0c
- 03/02/21
- Rigel Pharmaceuticals reports Q4 EPS (11c), consensus (11c)
- 01/11/21
- Rigel Pharmaceuticals sees Q4 revenue approximately $18.4M, consensus $17.81M
- 05/10/21
- uniQure reports Q1 EPS (91c), consensus (88c)
- 03/01/21
- uniQure reports 2020 EPS ($2.81), consensus ($1.25)
ORTX Orchard Therapeutics - 05/13/21
- Orchard Therapeutics reports Q1 EPS (31c), consensus (33c)
- 03/02/21
- Orchard Therapeutics reports Q4 net loss $33.6M vs. $45.4M last year
MGTA Magenta Therapeutics - 05/06/21
- Magenta Therapeutics reports Q1 EPS (36c), consensus (40c)
- 03/03/21
- Magenta Therapeutics reports Q4 EPS (38c), consensus (41c)
- 05/06/21
- MEI Pharma reports Q3 EPS (28c), consensus (16c)
- 02/04/21
- MEI Pharma reports Q2 EPS (16c), consensus (13c)
- 05/14/21
- Mustang Bio reports Q1 EPS (19c), consensus (19c)
- 03/24/21
- Mustang Bio reports FY20 EPS ($1.14), consensus ($1.01)
- 03/25/21
- Keros Therapeutics reports Q4 EPS (49c), consensus (57c)
JAZZ Jazz Pharmaceuticals - 05/04/21
- Jazz Pharmaceuticals backs FY21 adjusted EPS view $15.65-$16.85
- 05/04/21
- Jazz Pharmaceuticals reports Q1 EPS $3.92, consensus $3.71
- 02/23/21
- Jazz Pharmaceuticals sees FY21 adjusted EPS $15.65-$16.85, consensus $16.78
- 02/23/21
- Jazz Pharmaceuticals reports Q4 EPS $4.00, consensus $4.20
- 05/04/21
- Incyte reports Q1 EPS 67c, consensus 64c
- 02/09/21
- Incyte reports Q4 EPS 93c, consensus 75c
- 02/08/21
- Notable companies reporting before tomorrow's open
- 05/11/21
- Imara reports Q1 EPS (58), two est. (83c)
- 03/05/21
- Imara reports 2020 EPS ($3.53), consensus ($3.82)
GBT Global Blood Therapeutics - 05/05/21
- Global Blood Therapeutics reports Q1 EPS ($1.21), consensus ($1.01)
- 02/24/21
- Global Blood Therapeutics reports Q4 EPS ($1.00) , consensus (94c)
- 05/14/21
- Forma Therapeutics reports Q1 EPS (76c), consensus (76c)
- 03/30/21
- Forma Therapeutics reports Q4 EPS (68c), consensus (80c)
- 05/13/21
- Equillium reports Q1 EPS (33c), consensus (32c)
- 05/13/21
- Equillium reports Q1 EPS (33c), consensus (32c)
- 03/24/21
- Equillium reports Q4 EPS (36c), consensus (38c)
- 05/06/21
- Epizyme reports Q1 EPS (69c), consensus (57c)
- 02/23/21
- Epizyme reports Q4 EPS (65c), consensus (58c)
- 05/12/21
- Curis reports Q1 EPS (11c), consensus (9c)
- 03/16/21
- Curis reports Q4 EPS (11c), consensus (9c)
- 05/06/21
- BeiGene reports Q1 EPS 69c vs. ($4.70) a year ago.
- 02/25/21
- BeiGene reports Q4 EPS ($5.20), consensus ($4.81)
- 03/23/21
- Aptose Biosciences reports Q4 EPS (17c), consensus (14c)
- 04/28/21
- Apellis reports Q1 EPS ($2.32), consensus ($1.62)
- 02/25/21
- Apellis reports Q EPS 93c, consensus (75c)
- 04/30/21
- Alexion reports Q1 EPS $3.52, consensus $3.16
- 02/04/21
- Alexion reports Q4 EPS $2.96, consensus $2.56
- 02/04/21
- Alexion reports Q4 EPS $2.96, consensus $2.56
AGIO Agios Pharmaceuticals - 04/29/21
- Agios Pharmaceuticals reports Q1 EPS ($1.31), consensus ($1.32)
- 02/25/21
- Agios Pharmaceuticals reports Q4 EPS ($1.41), consensus ($1.33)
|
|
Conference/Events
|
Conference call with… Conference call with management will be held on June 15 at 11 am hosted by Truist. ShowHide Related Items >><< - 06/07/21
- MEI Pharma, Kyowa Kirin announce first patient dosed in phase 2 TIDAL study
- 05/12/21
- MEI Pharma, Kyowa Kirin to present data from Phase 1b study of zandelisib combo
- 04/30/21
- MEI Pharma promotes Richard Ghalie to Chief Medical Officer
- 04/13/21
- MEI Pharma completes enrollment in Phase 2 Tidal study
- 04/26/21 Wells Fargo
- MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
- 10/12/20 Brookline
- MEI Pharma initiated with a Buy at Brookline
- 09/22/20 Alliance Global Partners
- MEI Pharma initiated with a Buy at Alliance Global Partners
- 07/06/20 Truist
- MEI Pharma price target lowered to $12 from $16 at SunTrust
- 05/06/21
- MEI Pharma reports Q3 EPS (28c), consensus (16c)
- 02/04/21
- MEI Pharma reports Q2 EPS (16c), consensus (13c)
|